南方医科大学学报 ›› 2016, Vol. 36 ›› Issue (02): 210-.

• • 上一篇    下一篇

鳖甲煎丸对HepG2裸鼠移植瘤的抑制作用及瘤体组织中β-catenin、Tbx3表达水平的影响

文彬,孙海涛,贺松其,腊蕾,安海燕,庞杰   

  • 出版日期:2016-02-20 发布日期:2016-02-20

Inhibitory effect of Biejiajian pills on HepG2 cell xenograft growth and expression of β-catenin and Tbx3 in nude mice

  • Online:2016-02-20 Published:2016-02-20

摘要: 目的通过研究鳖甲煎丸对人肝癌HepG2裸鼠移植瘤生长的抑制作用及Wnt/β-catenin信号通路相关蛋白表达的影响,探
讨鳖甲煎丸抗肝细胞癌的分子机制。方法裸鼠成瘤实验观察鳖甲煎丸对人肝癌HepG2裸鼠移植瘤生长的抑制作用,免疫组织
化学法检测人肝癌HepG2裸鼠移植瘤组织中PCNA的表达水平,TUNEL法检测人肝癌HepG2裸鼠移植瘤细胞凋亡,Western
blot检测人肝癌HepG2裸鼠移植瘤组织中β-catenin和Tbx3的表达水平。结果鳖甲煎丸能够显著抑制人肝癌HepG2裸鼠移植
瘤的生长(P<0.05);和阴性对照(NC)组(5.5±0.90)相比,高剂量(H)组(22.9±1.22)、中剂量(M)组(14.7±0.50)移植瘤细胞凋亡率
显著增加(P<0.05);H(40.9±2.31)、M(53.5±2.41)、低剂量(L)组(62.3±1.80)与NC组(93.5±1.70)相比,PCNA阳性细胞比例显
著降低(P<0.05);同时,鳖甲煎丸能够抑制Wnt/β-catenin信号通路的信号分子β-catenin和Tbx3的表达。结论鳖甲煎丸抗肝细
胞癌的作用机制可能与抑制PCNA的表达以及调控Wnt/β-catenin信号通路相关蛋白表达水平有关。

Abstract: Objective To explore the molecular mechanism by which Biejiajian pills inhibit hepatocellular carcinoma in a nude
mouse model bearing HepG2 cell xenograft. Methods The inhibitory effect of Biejiajian pills on the growth of HepG2 cell
xenograft in nude mice was observed. Immunohistochemical method was used to examine proliferating cell nuclear antigen
(PCNA) expression in HepG2 cell xenograft, and TUNEL method was employed to detect the cell apoptosis; the expression
levels of β-catenin and Tbx3 were measured by Western blotting. Results Biejiajian pills significantly suppressed the growth of
HepG2 cell xenograft in nude mice. The tumor-bearing mice treated with a high and a moderate dose of Biejiajian pills showed
significantly increased apoptosis rate of the tumor cells [(22.9 ± 1.220)% and (14.7 ± 0.50)% , respectively] compared with the
control group [(5.5±0.90)%, P<0.05]. Treatment with Biejiajian pills significantly decreased the expressions of PNCA, β-catenin,
and Tbx3 in the cell xenograft (P<0.05). Conclusion Biejiajian pills can inhibit the growth of HepG2 cell xenograft in nude mice
and promote tumor cell apoptosis possibly by inhibiting PNCA expression and the Wnt/β-catenin signaling pathway.